CUE
Cue Biopharma, Inc.
There isn't enough reported data to score CUE yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CUE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
CUE's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CUE PE Valuation
CUE has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CUE Forward outlook
There aren't enough analyst estimates for CUE to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CUE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$25.82 | -$9.92 |
| Q1 2026 | -$4.38 | +$14.82 |
| Q4 2025 | -$8.40 | +$13.20 |
| Q3 2025 | -$12.90 | +$14.40 |
| Q2 2025 | -$15.90 | +$13.50 |
| Q1 2025 | -$19.20 | +$12.90 |
| Q4 2024 | -$21.60 | +$11.70 |
| Q3 2024 | -$27.30 | +$8.40 |
CUE is still losing money, but far less than before: $25.82 per share over the past year, against $57.00 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CUE on earnings quality, reporting a profit while its opponent remains loss making.
CUE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.9M | +167% |
| Q1 2026 | $5.7M | +1251% |
| Q4 2025 | $21.9M | +1292% |
| Q3 2025 | $2.1M | -36% |
| Q2 2025 | $3M | +11% |
| Q1 2025 | $421K | -75% |
| Q4 2024 | $1.6M | -13% |
| Q3 2024 | $3.3M | +59% |
CUE's revenue is growing: $8M last quarter, up 167% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1113% | -821 points |
| Q1 2026 | -94% | +2827 points |
| Q4 2025 | 9% | +620 points |
| Q3 2025 | -353% | -89 points |
| Q2 2025 | -292% | +98 points |
| Q1 2025 | -2921% | -2184 points |
| Q4 2024 | -611% | +148 points |
| Q3 2024 | -264% | +280 points |
CUE's operating margin was −1113% last quarter, down 821 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CUE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CUE on profitability, with a higher operating margin.
CUE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$29M | -$25.6M |
| Q1 2026 | -$11.1M | -$2.7M |
| Q4 2025 | -$1.1M | +$8M |
| Q3 2025 | -$9M | -$1.5M |
| Q2 2025 | -$3.4M | +$6.6M |
| Q1 2025 | -$8.3M | +$1.5M |
| Q4 2024 | -$9M | +$1.9M |
| Q3 2024 | -$7.5M | +$273K |
CUE has burned cash in almost every quarter: −$50M over the past year, against −$28M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CUE on cash generation, producing positive trailing cash flow while its opponent burns cash.
CUE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +32% | +1.5M shares |
| 1 year | +99% | +3.2M shares |
| 3 years | +325% | +4.8M shares |
| 5 years | +509% | +5.3M shares |
| Available history | +747% | +5.6M shares |
CUE has 6M diluted shares, up 99% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $127 |
| Q3 2022 | $9,000 |
| Q2 2022 | — |
| Q1 2022 | $191,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over CUE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CUE Net Leverage
CUE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CUE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.8 | Neutral |
| Stochastic | 12.2 | Oversold |
CUE's weekly RSI is 44 (neutral) and its Stochastic is 12 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CUE PE vs Healthcare Sector
CUE has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CUE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.1 | 21% below |
| 20 week MA | $26.9 | 35% below |
| 50 week MA | $20.1 | 13% below |
| 100 week MA | $23.3 | 25% below |
| 200 week MA | $46.7 | 63% below |
CUE is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CUE on trend strength, trading above more of its moving averages.
CUE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $524.1 | $393.6 | -25% |
| 2021 | $393.6 | $373.2 | -5.2% |
| 2022 | $373.2 | $82.5 | -78% |
| 2023 | $82.5 | $79.2 | -4% |
| 2024 | $79.2 | $31.2 | -61% |
| 2025 | $31.2 | $9.74 | -69% |
| 2026 YTD | $9.74 | $17.5 | +80% |
CUE has finished every year since 2020 lower, and it's up 80% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CUE on returns for 2026, with the stronger performance.